RT Journal Article
SR Electronic
A1 Boltz, Kathy
T1 The PAOLA Study
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 4
SP 8
OP 10
DO 10.1177/1559897715582168
UL http://mdc.sagepub.com/content/15/4/8.2.abstract
AB Pasireotide LAR had a dose-proportional relationship with dose exposure over a 40- to 60-mg range. Efficacy end points of levels of growth hormone and IGF-1 were correlated with pasireotide exposure, and response rates were higher at the higher pasireotide dose.